Código QR (código de barras bidimensional)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Abstract Background While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn’s disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutan...

Fuld beskrivelse

Na minha lista:
Principais autores: Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Marc Ferrante, Jordi Guardiola, Jørgen Jahnsen, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Philip J Smith, Taek Kwon, Jeeyoung Kim, Sangwook Yoon, Dong-Hyeon Kim, Raja Atreya
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2024-03-01
Serier:BMC Gastroenterology
Fag:
Biobetter
Bioinnovative
Inflammatory bowel disease
Subcutaneous infliximab
Tumour necrosis factor-α inhibitors
Vedolizumab
Online adgang:https://doi.org/10.1186/s12876-024-03163-5
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker